Multiple Sclerosis, Cannabis Use, and Clinical Disability: A Preliminary [(18)F]-Fluorodeoxyglucose Positron Emission Tomography Study

Introduction: Long-term consequences of medicinal cannabis use in people with multiple sclerosis (PwMS) are unknown. This study investigated whether PwMS using cannabis had lower resting brain glucose uptake (GU) and worse clinical test results compared with nonusers. Methods: Sixteen PwMS, eight us...

Descripción completa

Detalles Bibliográficos
Autores principales: Kindred, John H., Honce, Justin M., Kwak, Jennifer J., Rudroff, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186162/
https://www.ncbi.nlm.nih.gov/pubmed/30324138
http://dx.doi.org/10.1089/can.2018.0019
Descripción
Sumario:Introduction: Long-term consequences of medicinal cannabis use in people with multiple sclerosis (PwMS) are unknown. This study investigated whether PwMS using cannabis had lower resting brain glucose uptake (GU) and worse clinical test results compared with nonusers. Methods: Sixteen PwMS, eight users, underwent clinical testing followed by [(18)F]-Fluorodeoxyglucose positron emission tomography/computed tomography imaging. Results: Users had lower cognitive function test scores, but performed similarly on the other clinical evaluations. Accounting for disease duration, resting brain GU was similar between the groups. Conclusions: Lower cognitive function was not associated with resting brain GU. Cognitive dysfunction may be a contraindication or consequence of cannabis use in PwMS.

Ejemplares similares